Abstract
目的分析原发性血小板增多症(ET)患者基因突变谱及临床特征。方法对2009年2月1日至2018年11月1日收治的178例初诊ET患者进行回顾性分析。结果全部178例患者中,男89例,女89例,中位初诊年龄为49.5(3~86)岁。JAK2V617F基因突变频率为16.45%(1.67%~43.90%),CALR基因突变频率为40.00%(10.00%~49.15%),MPL基因突变频率为25.10%(25.00%~40.00%)。与CALR基因突变的患者相比,JAK2V617F基因突变患者具有较高的发病年龄(P=0.035)、初诊白细胞计数(P=0.040)、初诊血红蛋白浓度(P=0.001)和较低的初诊血小板计数(P=0.002)。47例(27.01%)患者诊断ET前发生血栓事件,3例(1.72%)诊断ET后发生血栓事件。多因素分析结果显示,年龄>60岁(P=0.013,OR=4.595,95%CI1.382~15.282)、心血管危险因素(P<0.001,OR=8.873,95%CI2.921~26.955)为血栓事件的危险因素,CALR基因突变(P=0.032,OR=0.126,95%CI0.019~0.838)为血栓事件的保护性因素。年龄>60岁(P=0.042,OR=4.045,95%CI1.053~15.534)是影响ET患者总生存时间的危险因素。年龄≤60岁、年龄>60岁患者的OS时间分别为(115.231±1.899)、(83.291±4.991)个月(χ2=6.406,P=0.011)。结论心血管危险因素、年龄>60岁为ET患者血栓事件的危险因素,CALR基因突变为血栓事件的保护性因素。年龄>60岁是影响ET患者总生存的危险因素。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.